7 Results
October/November 2008
- Multi-lab Evaluation of Expression Profiling Platforms
Stephen M. Tirrell, Ph.D. Director of Molecular Technologies Michael D. Pickard, Senior Biostatistician Erik M. Koenig Manager within Molecular Technologies MILLENNIUM: The Takeda Oncology Company
- Translational Medicine Perspectives in Drug Discovery and Development-Part V:
Giora Z. Feuerstein M.D. Assistant Vice President and Head of Discovery Translational Medicine Wyeth Research Frank Walsh, Ph.D. Head of Discovery Research Worldwide Wyeth Pharmaceuticals Charles Dormer Assistant Vice President, Discovery Operation and Portfolio Management Wyeth Research Steve Douglas, Ph.D.Director of Discovery Translational Medicine Wyeth Research
- FDA Perspectives on Validating Proteomic Biomarkers for In Vitro Diagnostic Use
Reena Philip, Ph.D Scientific Reviewer, Division of Immunology, Office of In Vitro Diagnostic Device Evlauation and Safety CDRH, Maria M. Chan, Ph.D.Associate Director, Division of Immunology and Hematology Devices, Office of In Vitro Diagnostic Device Evaluation and Safety FDA, Steven I. Gutman, MDDirector, Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH
- Lead Identification at Abbott Laboratories: Lessons Learned and Future Trends
Duncan R. Groebe, Ph.D. Research Investigator, Centralized High-Throughput Screening Group, Usha Warrior, Ph.D.Project Leader, Centralized High-Throughput Screening Group, David J. Burns, Ph.D. Global Head of HTS, Advanced Technology, Abbott Laboratories
- Integration of Novel Technologies in Discovery and Early Development Toxicology
Scott E. Warder, Ph.D. Research Investigator, Cellular, Molecular and Exploratory Toxicology, Shaun M. McLoughlin, Ph.D. Associate Research Investigator Protein Mass Spectrometry, Paul M. Jung, Ph.D.Associate Research Investigator, Gene Expression Analysis,Eric Blomme, PH.D. D.V.M., D.A.C.V.P., Sr. Project Leader, Cellular, Molecular and Exploratory Toxicology, Abbott Laboratories
- Common Challenges and Considerations for Standardization and Validation of Gene Expression Assays
Bharat H. Joshi, Ph.D. Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration
- Global Challenges in Compound Management:
Christine Rigby Associate Director, Global Compound Sciences AstraZeneca